Why Oncology Logistics Demands More Than Any Other Medical Courier Category
Cancer care is built on precision. The chemotherapy regimen prescribed for a patient with breast cancer is not an approximation. It is a protocol designed around specific drugs, specific doses, specific timing intervals, and specific biological targets identified through diagnostic testing that was itself dependent on specimen quality, fixation accuracy, and the reliability of the immunohistochemical and molecular platforms used to classify the tumour. Every component of that precision depends, at some point, on logistics. In oncology more than in almost any other clinical specialty, what happens during transport has direct consequences for what happens during treatment.
The Diagnostic Phase: Where Oncology Logistics Begins
The oncology logistics challenge begins before a diagnosis is confirmed. A core needle biopsy of a breast mass assessed for oestrogen receptor, progesterone receptor, HER2, and Ki-67 status requires handling that meets specific fixation time requirements if those biomarker results are to be reliable. Cold ischaemia time must be minimised. Fixation time in 10% neutral buffered formalin must fall within the 6 to 72 hour window specified in international guidelines. The transport from the biopsy suite to the pathology laboratory must not extend the pre-fixation ischaemia time unnecessarily, and must not expose the specimen to conditions that accelerate autolysis before fixation is complete.
Liquid biopsy specimens, where circulating tumour DNA or circulating tumour cells are isolated from peripheral blood for molecular profiling, have particularly strict handling requirements. These specimens must be collected into specific stabilisation tubes, processed within defined time windows, and transported under conditions that prevent cell lysis and DNA degradation. A liquid biopsy specimen that arrives at the molecular laboratory outside its handling window may produce a result that underestimates tumour DNA concentration or fails to detect mutations that are present in the circulation, with direct implications for treatment selection and monitoring.
Chemotherapy Logistics: A Category With No Room for Error
Chemotherapy agents are among the most pharmacologically active and biologically hazardous
substances transported in any medical logistics context. They are cytotoxic by design, targeting rapidly
dividing cells in a way that is therapeutically useful against tumour cells and potentially harmful to any
other tissue they contact. The preparation of chemotherapy infusions involves the compounding of precise
doses under aseptic conditions, with shelf lives defined by the stability of the drug in solution at the
specified storage temperature. Temperature requirements vary by agent. Monoclonal antibody therapies including trastuzumab, bevacizumab, and rituximab require refrigeration at 2 to 8 degrees Celsius. Some targeted agents have specific light sensitivity requirements in addition to temperature requirements.
A chemotherapy preparation that was correctly compounded, correctly labelled, and correctly dispensed, and then transported in conditions that compromised its stability, is a preparation that may have reduced potency, altered pharmacokinetics, or in the case of biological agents, altered immunogenicity. The patient who receives it may receive an inadequate dose of a critical treatment. The clinical team administering it has no basis on which to detect the compromise, because the preparation looks correct and the documentation says it arrived.
Biologic Therapies and the Home Administration Challenge
An increasing proportion of oncology treatment is administered in the home rather than in hospital infusion centres. Subcutaneous formulations of monoclonal antibodies, oral targeted therapies, and supportive care medications are prescribed for home administration in growing numbers. A patient receiving subcutaneous trastuzumab for HER2 positive breast cancer at home depends on a medication that requires refrigeration at 2 to 8 degrees Celsius, that has a cost per dose that may run to several thousand rands, and whose therapeutic efficacy depends on receiving the correct dose at the correct interval in a preparation that has retained its potency throughout storage and transit.
A delivery arrangement that cannot guarantee temperature maintenance during transit, that cannot provide a temperature record at the point of delivery, and that cannot confirm delivery to the correct patient at the correct address is not an adequate logistics arrangement for a biologic oncology therapy. The documentation requirement for home delivery of oncology medications is more demanding than for most other pharmaceutical categories, because the clinical and regulatory consequences of delivery failure are more severe and because the chain of evidence from pharmacy to patient must be unbroken to support any subsequent investigation of treatment outcome.
Tumour Marker Monitoring: The Ongoing Specimen Logistics Requirement
Cancer treatment does not end the specimen logistics requirement. It intensifies it. Patients receiving chemotherapy require regular blood sampling to monitor haematological toxicity, renal and hepatic function, and tumour marker response. In an oncology patient who is immunocompromised from treatment, the blood count that determines whether the next cycle of chemotherapy can proceed must be accurate. A falsely elevated white cell count from a haemolysed or delayed specimen may allow a cycle to proceed that should be delayed. A falsely depressed neutrophil count may cause an unnecessary treatment delay. In either case, the clinical decision was shaped not by the patient’s actual haematological status but by the quality of the specimen that represented it.
Tumour markers such as CA-125 in ovarian cancer, PSA in prostate cancer, CEA in colorectal cancer, and
AFP in hepatocellular carcinoma are used to monitor treatment response and detect recurrence. Their
interpretation is highly dependent on consistent analytical conditions across serial measurements. A result
affected by haemolytic interference, by prolonged storage, or by temperature excursion during transport
may show apparent marker elevation that is artefactual rather than clinical, prompting unnecessary
investigation or treatment escalation. For patients in long-term follow-up after curative treatment, a false positive from a compromised specimen is not a laboratory inconvenience. It is a clinical and psychological event.
Molecular Profiling and the Precision Medicine Requirement
Oncology is increasingly a discipline of molecular precision. Next generation sequencing panels, companion diagnostic tests, and predictive biomarker assays are now integral to treatment selection in many tumour types. The results of these analyses determine whether a patient receives a targeted therapy, whether they are eligible for a clinical trial, and in some cases whether treatment with curative intent is viable. These analytical platforms are entirely dependent on receiving adequate, well-preserved nucleic acid from the specimens submitted for analysis. DNA and RNA are subject to degradation by nucleases that remain active until the tissue is adequately fixed or the nucleic acid is extracted and stabilised.
A poorly handled biopsy specimen, one that experienced extended pre-fixation ischaemia time, inadequate fixative volume, or fixation at an inappropriate temperature, may yield nucleic acid that is too fragmented or too poorly preserved for reliable next generation sequencing. The result is either a failed assay with no reportable result, or a result of reduced confidence that may miss low frequency mutations relevant to treatment selection. In a clinical context where a single mutation, a single amplification, or a single translocation may determine eligibility for a therapy that could substantially alter a patient’s prognosis, the quality of the specimen transport that delivered the biopsy to the pathology laboratory is not a logistical detail. It is a determinant of whether the molecular information needed to guide treatment is available at all.
Building an Oncology Logistics Framework
The logistics requirements of an oncology practice, oncology pharmacy, or cancer centre are not adequately met by the logistics arrangements that suffice for a general medical practice. They require a courier partner who understands the specific requirements of oncology specimen types, the cold chain and documentation obligations for cytotoxic and biologic therapies, the urgency categories that apply to different specimen types in the diagnostic workup, and the standard of proof of delivery and temperature documentation that oncology practice requires. They require a STAT capability for urgent specimens, a communication system that is responsive to the time sensitive nature of oncology logistics events, and a documentation system that produces the chain of custody and temperature records that oncology practice needs for clinical, regulatory, and medico-legal purposes.
